Onconetix Inc., a biotechnology company specializing in men's health and oncology, has announced a 1-for-85 reverse stock split effective June 13, 2025. This move, approved at the company's recent special stockholder meeting, will reduce the number of outstanding shares from approximately 44.4 million to 521,863. The company aims to regain compliance with Nasdaq's minimum bid price requirement of $1.00 per share. Onconetix will continue trading under the symbol "ONCO" with a new CUSIP number.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.